Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines

被引:41
作者
Al-Ejeh, F [1 ]
Croucher, D [1 ]
Ranson, M [1 ]
机构
[1] Univ Wollongong, Dept Biol Sci, Wollongong, NSW 2522, Australia
关键词
cancer cells; endocytosis; inactivation constant (K-I); inactivation rate constant (k(inact)); plasminogen activator inhibitor type-2 (PAI-2); urokinase (uPA);
D O I
10.1016/j.yexcr.2004.03.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overexpression of urokinase (uPA), which plays a key role in tumour invasion and metastasis, is an established prognostic marker and potential therapeutic target. Plasminogen activator inhibitor type 2 (PAI-2), an efficient and specific inhibitor of uPA, has been shown to selectively deliver potent cytotoxins to tumour cells. However, a direct quantitative analysis of both the inhibition kinetics and subsequent fate of PAI-2 upon interaction with cell-surface uPA has not been previously undertaken. In this study, we analysed specific PAI-2 binding to receptor-bound uPA on human breast and prostate cancer cell lines to directly measure inhibition kinetics. Cell-surface uPA:PAI-2 complex formation, which is reflective of complete uPA inhibition, was found to be very efficient (inactivation constant [K-1] = 60-80 pM, depending on cell line used) and rapid (inactivation rate constant [k(inact)] = 0.32-0.47 min(-1) at 37degreesC, depending on cell line used). To directly quantify and visualise cellular internalisation and localisation, we developed a novel assay based on the use of PAI-2 labelled with Alexa(488) fluorochrome and a polyclonal antibody to quench Alexa(488) fluorescence. The efficient and rapid formation of uPA:PAI-2 complexes was thus shown to be associated with specific and rapid internalisation of PAI-2, which could be localised within endosomes and lysosomes. PAI-2 was subsequently degraded, presumably within lysosomes. This study is the first to provide definitive evidence for uPA/uPAR-mediated PAI-2 endocytosis. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:259 / 271
页数:13
相关论文
共 48 条
[31]   The low-density lipoprotein receptor gene family: a cellular Swiss army knife? [J].
Nykjaer, A ;
Willnow, TE .
TRENDS IN CELL BIOLOGY, 2002, 12 (06) :273-280
[32]   Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth [J].
Ossowski, L ;
Aguirre-Ghiso, JA .
CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (05) :613-620
[33]   PROUROKINASE ACTIVATION ON THE SURFACE OF HUMAN RHABDOMYOSARCOMA CELLS - LOCALIZATION AND INACTIVATION OF NEWLY FORMED UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY RECOMBINANT CLASS-2 PLASMINOGEN-ACTIVATOR INHIBITOR [J].
POLLANEN, J ;
VAHERI, A ;
TAPIOVAARA, H ;
RILEY, E ;
BERTRAM, K ;
WOODROW, G ;
STEPHENS, RW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (06) :2230-2234
[34]  
QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793
[35]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR TYPE-2 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEXES ARE NOT INTERNALIZED UPON BINDING TO THE UROKINASE-TYPE-PLASMINOGEN-ACTIVATOR RECEPTOR IN THP-1 CELLS - INTERACTION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR TYPE-2 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEXES WITH THE CELL-SURFACE [J].
RAGNO, P ;
MONTUORI, N ;
ROSSI, G .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1995, 233 (02) :514-519
[36]   Role of plasminogen activator-plasmin system in tumor angiogenesis [J].
Rakic, JM ;
Maillard, C ;
Jost, M ;
Bajou, K ;
Masson, V ;
Devy, L ;
Lambert, V ;
Foidart, JM ;
Noël, A .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (03) :463-473
[37]   In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells [J].
Ranson, M ;
Tian, Z ;
Andronicos, NM ;
Rizvi, S ;
Allen, BJ .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 71 (02) :149-159
[38]   Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins [J].
Ranson, M ;
Andronicos, NM ;
O'Mullane, MJ ;
Baker, MS .
BRITISH JOURNAL OF CANCER, 1998, 77 (10) :1586-1597
[39]   CLONING AND EXPRESSION OF THE RECEPTOR FOR HUMAN UROKINASE PLASMINOGEN-ACTIVATOR, A CENTRAL MOLECULE IN CELL-SURFACE, PLASMIN DEPENDENT PROTEOLYSIS [J].
ROLDAN, AL ;
CUBELLIS, MV ;
MASUCCI, MT ;
BEHRENDT, N ;
LUND, LR ;
DANO, K ;
APPELLA, E ;
BLASI, F .
EMBO JOURNAL, 1990, 9 (02) :467-474
[40]   Immunological detection of conformational neoepitopes associated with the serpin activity of plasminogen activator inhibitor type-2 [J].
Saunders, DN ;
Buttigieg, KML ;
Gould, A ;
McPhun, V ;
Baker, MS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :10965-10971